Introduction
Plant stress hormones of the jasmonate family, small hydrophobic molecules, have been previously shown to be endowed with anticancer capabilities (Fingrut and Flescher, 2002; Ishii et al., 2004) , allowing for the prolonged survival of tumor-bearing animals (Fingrut and Flescher, 2002; Heyfets and Flescher, 2007) and suppression of the metastasis of murine melanoma . Indeed, jasmonates are selectively toxic toward cancer cells (Fingrut and Flescher, 2002; Rotem et al., 2005) . In the leukemic cell line, Molt-4, the cytotoxicity of methyl jasmonate (MJ) was shown to be transcription-and translation-independent (Flescher, 2005) . In addition, the jasmonates are effective against drug-resistant cells Flescher, 2005; Reischer et al., 2007) .
Recently, it was reported that jasmonates directly affect the mitochondrial function of cancer cells . Mitochondria serve many functions apart from their central bioenergetics role of supplying adenosine 5 0 -triphosphate (ATP), including assuming a central role in the process of cell death. Mitochondriamediated apoptosis results in the efflux of a number of potential apoptotic regulators, such as cytochrome c, to the cytosol, triggering caspase activation and cell destruction. Upon exposure to adverse conditions, permeability transition of mitochondria, mediated by the permeability transition pore complex (PTPC), can be initiated. The central components of the PTPC include the adenine nucleotide translocator, cyclophilin D, and the voltage-dependent anion channel (VDAC). Prolonged opening of the PTPC leads to dissipation of the inner membrane mitochondrial potential, osmotic swelling of mitochondrial matrix, release of cytochrome c and ultimately cell death by either necrosis or apoptosis (Lemasters et al., 1998; Debatin et al., 2002; Green and Kroemer, 2004; Galuzzi et al., 2006; Kroemer, 2006) . Jasmonates were shown to induce perturbation of mitochondria isolated from several different cancer cell lines, as well as in lymphocytes drawn from chronic lymphocytic leukemia patients . PTPC inhibitors, cyclosporine A and bongkrekic acid, were able to block these effects, further suggesting the PTPC-based mechanism of action of jasmonates. In contrast, jasmonates did not induce mitochondrial perturbation and were nontoxic in normal lymphocytes or nontransformed 3T3 cells (Fingrut and Flescher, 2002; Rotem et al., 2005) .
Cancer mitochondria differ from normal mitochondria in numerous aspects. These include a higher mitochondrial membrane potential, modulation of the expression of PTPC components and enhanced rates of ATP generation through glycolysis rather than through oxidative phosphorylation (a phenomenon known as the Warburg effect) in cancer cells (Warburg et al., 1930; Pedersen, 1978 Pedersen, , 2007a Dang and Semenza, 1999; Cuezva et al., 2002; Debatin et al., 2002; Pedersen et al., 2002; Kroemer, 2003 Kroemer, , 2006 Isidoro et al., 2004; Hay, 2005, 2006; Galuzzi et al., 2006; Mathupala et al., 2006) , possibly explaining the selective action of jasmonates on such cells. Indeed, we have found that jasmonates cause significant decreases in cellular ATP levels in cancer, but not in normal cells Goldin et al., 2007; Heyfets and Flescher, 2007) . Moreover, positive correlation between the susceptibility of a given cell type to the cytotoxic effect of MJ and the degree of ATP depletion induced in that cell was shown (Goldin et al., 2007) . In accordance with mitochondria being the target organelles of MJ, such decreases in ATP levels were found to be independent of pyruvate and oligomycin, a substrate and an inhibitor of oxidative phosphorylation, respectively, suggesting the effect of MJ on the mitochondrial ATP generation to be massive and irreversible . On the other hand, glucose conferred protection against MJinduced decreases in ATP levels, whereas the glycolysis inhibitor, 2-deoxyglucose, showed synergistic effects when administered in combination with MJ Heyfets and Flescher, 2007) .
Given the potential importance of jasmonates as a novel class of selective anticancer drugs, it is important to analyse the mechanism of jasmonate action and identify their target molecules. First, understanding the mechanism of jasmonate action will enhance our ability to foresee the clinical settings in which these agents would be effective as anticancer agents, as well as their potential side effects. Second, identifying the target molecule with which these anticancer compounds interact would allow for the rational design of more potent jasmonate derivatives.
Hexokinase is the initial and key enzyme in the glycolytic pathway. It binds to the mitochondrial VDAC through a hydrophobic interaction (Nakashima et al., 1986) . Recently, it was found that its isozymes, hexokinase type I and hexokinase type II, can associate with VDAC via their hydrophobic N termini. Dissociation of hexokinase from VDAC leads to mitochondrial perturbation and promotes cell death (Azoulay-Zohar et al., 2004; Majewski et al., 2004; Pastorino et al., 2005) . In cancer cells, mitochondria-bound hexokinase and VDAC are overexpressed (Pedersen et al., 2002) . The elevated levels of mitochondria-bound hexokinase in cancer cells, as well as its glucose phosphorylation activity, are suggested to play a pivotal role in cancer cell growth rate and survival by both improving energy supplies and protecting against mitochondria-mediated cell death (Bustamante and Pedersen, 1977; Hammerman et al., 2004; Sun et al., 2008) . As such, hexokinase, types I and II in particular, is considered as an attractive target for anticancer therapy (Pedersen et al., 2002; Kroemer, 2003 Kroemer, , 2006 ; Azoulay-Zohar et al., 2004; Majewski et al., 2004; Hay, 2005, 2006; Zaid et al, 2005; Galuzzi et al., 2006; Mathupala et al., 2006; Pedersen, 2007a, b) . With this in mind, the goal of our study was to investigate whether hexokinase or VDAC-associated hexokinase represents the molecular target(s) of jasmonates. We report that MJ directly binds to hexokinase, interferes with hexokinase-VDAC interaction and dissociates hexokinase from mitochondria. Furthermore, MJ perturbs only hexokinase-bound mitochondria, whereas hexokinase overexpression decreases MJ-induced cytotoxicity. As such, we present the first demonstration of an anticancer cytotoxic agent binding directly to hexokinase.
Results
Mitochondria-associated hexokinase is the target of MJ MJ detaches hexokinase from the mitochondrial fraction of cancer cells. Methyl jasmonate directly perturbs mitochondria in a PTPC-dependent manner . We examined whether MJ is able to detach hexokinase from the mitochondrial fraction (MF) isolated from CT26 tumors by measuring hexokinase Figure 1) . The detachment of both hexokinase types by MJ as well by the hexokinase reaction product, glucose-6 phosphate (G6P) (Wilson and Chung, 1989) , was of a similar order of magnitude. However, there was a notable difference in the extent of hexokinase detachment as revealed by the activity assay versus western blotting. Under the experimental conditions employed, MJ had no inhibitory effect on hexokinase activity. Therefore, the weaker release effect shown by activity measurements can be explained by a decrease in the activity of detached hexokinase, resulting from lower affinity to ATP and higher susceptibility to feedback inhibition by G6P (Wilson, 1968 (Wilson, , 2003 .
MJ reopens hexokinase I-closed lipid bilayer-reconstituted VDAC channels. Mammalian hexokinase I and hexokinase II bind to the mitochondrial outer membrane via VDAC (Wilson, 2003; Azoulay-Zohar et al., 2004; Robey and Hay, 2006) . Hence, the effect of MJ on the channel activity of purified mitochondrial VDAC reconstituted into a planar lipid bilayer was studied under voltage clamp conditions (Gincel et al., 2001; AzoulayZohar et al., 2004) , an established method for examining VDAC interactions with hexokinase and other agents . In the absence of purified brain mitochondria hexokinase I, MJ, at the concentration used, had no effect on the current passing through VDAC in response to voltages stepped from a holding potential of 0-40 mV (Figure 2 ). At relatively low membrane potentials (À20 mV), conductance remained constant for up to 120 min of recording. Upon addition of purified hexokinase I, the open channel was stabilized in its low-conducting state. The effect of hexokinase I on VDAC channel opening was reversed by addition of MJ, reflecting the ability of MJ to disrupt the interaction between hexokinase I and VDAC. Similar results were obtained when reconstituted VDAC was exposed to a voltage of À40 mV, with hexokinase I promoting VDAC closure and stabilization at the subconductance state. Here too, addition of MJ led to reopening of the hexokinase I-closed channels (Figure 2 ).
MJ interacts with hexokinase I in a specific and dose-dependent manner. To probe a possible direct interaction between MJ and hexokinase I, real-time surface plasmon resonance (SPR) was performed. The advantage of SPR in investigating interactions involving small molecular-weight analytes, such as jasmonates, over conventional techniques such as fluorescence-based or enzyme-linked immunosorbent assays is the label-free and direct detection of an analyte, without the need for multistep detection protocols (Boozer et al., 2006) . Accordingly, it was shown that MJ binds to purified rat brain hexokinase I in a dose-dependent manner (Figure 3a) . However, determination of the dissociation constant was not possible because of the limited solubility of MJ in the buffer used. The specificity of MJ binding to hexokinase I was confirmed by the failure of MJ to bind to an irrelevant protein, rabbit immunoglobulin G (Figure 3b) . The less-cytotoxic jasmonate derivative, JA, did not bind to hexokinase I either (Figure 3c ).
Dissociation of the hexokinase-mitochondria interaction mediates MJ-induced mitochondria toxicity and cytotoxicity Mitochondrial damage and ATP depletion occur simultaneously with hexokinase release from the MF. As shown in Figure 4a , all cell lines tested exhibited a significant and dose-dependent decrease in cellular ATP levels following a 60-min exposure to MJ. Despite this massive depletion of ATP, cells exposed to 3 mM MJ remained alive after 60 min (Figure 4b ). Thus, in both Molt-4 (most sensitive to MJ-induced ATP depletion) and CT26 cells, ATP depletion precedes the appearance of dead cells. Cytochrome c release from the MF isolated from CT-26 tumors occurs within the same time frame (15-60 min) required to detach hexokinase from mitochondria ( Figure 4c ). Jasmonate detaches hexokinase from mitochondria N Goldin et al MJ induces swelling selectively in hexokinase-rich mitochondria. To examine whether the ability of MJ to detach bound hexokinase, eliciting mitochondrial damage, was restricted to tissues in which hexokinase is bound to mitochondria, the effect of MJ on brain and liver mitochondria was determined. It is established that rat brain MF is rich in bound hexokinase, whereas liver MF is devoid of it (Wilson, 1995) . We confirmed this difference in mice (data not shown). Next, we determined the ability of MJ to detach hexokinase from MF isolated from mouse brain (Figures 5a and b) . Consequently, we examined the ability of MJ to cause swelling in MF isolated from mouse brain and liver. As predicted by the above-mentioned relationship, treatment with Overexpression of hexokinase protects against MJinduced cytotoxicity. To examine the effect of hexokinase overexpression on MJ action, CT26 cells were transfected with plasmids, pcDNA3-HKII or pcDNA3, encoding for hexokinase II overexpression and a control plasmid, respectively (Zaid et al., 2005) . As shown in Figures 6a and b , both the depletion of cellular ATP levels and the overnight cytotoxicity induced by MJ were decreased in cells with higher expression of hexokinase II. Moreover, the cytotoxicity induced by staurosporine (Figure 6c ), a positive control (AzoulayZohar et al., 2004), was similarly decreased by hexokinase II overexpression.
Discussion
In this report, we present a novel cytotoxic mechanism by which jasmonates overcome the self-defense of cancer cells overexpressing hexokinase. We demonstrate that MJ is able to detach hexokinase from MF isolated from four different cancer types (both cancer cell lines and tumors extracted from animals). Moreover, each of these cancer cells was shown to express both hexokinase I and hexokinase II isozymes, which are able to bind to mitochondria.
Methyl jasmonate detached both hexokinase I and hexokinase II from mitochondria, in a time-and dosedependent manner. A plausible mechanism by which the hydrophobic jasmonates could induce dissociation of mitochondria-bound hexokinase from VDAC is by interfering with the documented hydrophobic interaction between these proteins (Ehsani-Zonouz et al., 2001 ). This hypothesis was tested using an in vitro model in which hexokinase was previously shown to stabilize the VDAC channel in a low-conductance state (Azoulay-Zohar et al., 2004) . Indeed, MJ was found to disrupt the hexokinase-VDAC interaction. Involvement of hexokinase detachment in the processes of jasmonateinduced mitochondrial damage was confirmed using brain and liver MF, serving as models for hexokinaserich and hexokinase-devoid mitochondria, respectively, as well as for CT26 cells overexpressing hexokinase. When overexpressed, hexokinase can protect mitochondria from the effect of MJ by one or more ways. The increased amount of cellular hexokinase will likely increase the occupation of the hexokinase mitochondrial-binding sites, thereby counteracting the dissociating effect of MJ. In accordance, the hexokinase II/ VDAC ratio in mitochondria of cells overexpressing hexokinase II is increased by about 80% (data not shown). Also, a portion of MJ molecules may bind to the excess cytosolic hexokinase molecules, thus becoming 'neutralized' before reaching mitochondrial hexokinase. The additive and even synergistic effect of combining MJ with the hexokinase inhibitor, deoxyglucose Heyfets and Flescher, 2007) , offers circumstantial support for this hypothesis.
Methyl jasmonate-induced detachment of mitochondria-bound hexokinase affects mitochondrial permeability as well as overall cellular bioenergetics. Fast and massive ATP depletion by jasmonate-induced hexokinase detachment fits with the fact that other agents known to detach mitochondrial hexokinase also induce ATP depletion preceding the decrease in cell viability (Miccoli et al., 1998; Machida et al., 2006) .
The less-cytotoxic and less-mitochondriotoxic jasmonate derivative, JA (Fingrut and Flescher, 2002) , is neither able to detach mitochondria-bound hexokinase nor to bind to hexokinase and cause significant swelling in hexokinase-rich brain mitochondria. However, JA was demonstrated to have a significant cytostatic effect on cancer cells (Fingrut and Flescher, 2002) and to affect the mitochondrial membrane potential of cancer cell lines . We, therefore, conclude that there is at least one additional mechanism (possibly indirect) by which jasmonates perturb cancer cell mitochondria. Figure 6 Overexpression of hexokinase protects against MJ-induced ATP depletion and cytotoxicity. CT26 cells were transfected with a hexokinase II-expressing vector (gray) or control plasmid (white). Cells were seeded in 96-well plates and allowed to adhere. (a) Cells were exposed to MJ for 60 min prior to ATP determination. (b) Cells were exposed to MJ for 24 h prior to cytotoxicity determination by the hemacolor method. (c) Cells were exposed to 3.75 mM staurosporine for 3 h prior to cytotoxicity determination by the hemacolor method. N ¼ 3. ATP, adenosine 5 0 -triphosphate; MJ, methyl jasmonate. *Po0.05 in comparison to untreated cells.
To the best of our knowledge, no jasmonate-binding protein was identified thus far, both in plants and in animals. We describe here the first jasmonate-binding protein, mammalian hexokinase. Jasmonates are a developing class of anticancer agents (Flescher, 2005 (Flescher, , 2007 Goldin et al., 2007) . In addition, jasmonates are important plant signal molecules (Chini et al., 2007) . In both cancer and plant-signaling fields, this discovery should encourage the search for additional target molecules of jasmonates.
Given the central role played by mitochondrial membrane permeabilization in apoptosis, the concept of apoptogenic compounds acting directly on the mitochondria of cancerous cells has become a focus of intense investigation (Pedersen, 2007a, b) . Controlling both bioenergetics and cell death (Pastorino and Hoek, 2003; Hammerman et al., 2004; Robey and Hay, 2005) , the hexokinase-mitochondria interaction has been considered as a target for anticancer drugs in recent years (Debatin et al., 2002; Kroemer, 2003 Kroemer, , 2006 Hay, 2005, 2006; Galuzzi et al., 2006; Mathupala et al., 2006) . Two main classes of agents affect mitochondrial hexokinase, that is hexokinase inhibitors and disruptors of hexokinase-mitochondria association. The first class includes competitive and/or allosteric antagonists of hexokinase activity (Wilson and Chung, 1989; Oudard et al., 1995; Brawer, 2005; Robey and Hay, 2005; Lampidis et al., 2006) . The second class includes compounds that compete for VDAC-or hexokinase-binding sites, such as hexokinase-binding domain peptides (Majewski et al., 2004) , VDAC1-based peptides (Arzoine L, Shoshan-Barmatz V (2006). VDAC1-based peptides interaction with hexokinase I as a new approach for cancer therapy. Presented in the 14 th Euroconference on Apoptosis, European Cell Death Organization. p15. www.ecdo.eu), agents covalently modifying VDAC (Robey and Hay, 2005) , G6P and its analogs (Wilson and Chung, 1989) , enzymes cleaving the N terminus of hexokinase that consists of the VDAC-binding site (Wilson, 2003) and agents with unknown mechanisms of action, such as hypericin and TH-070 (lonidamine) (Majewski et al., 2004; Robey and Hay, 2005) . In comparison with the above-mentioned agents, only MJ was demonstrated to bind to hexokinase directly and detach it from VDAC. All of the described agents have some disadvantages such as unclear or low specificity, or cell-permeabilization issues affecting their potential clinical use. On the other hand, MJ is clearly cancer cell-specific and cell permeable.
In many cases, hexokinase detachment by itself is insufficient to cause cell death (Penso and Beitner, 2003; Majewski et al., 2004) . Notably, jasmonates are distinct in their ability to cause considerable cell cytotoxicity by themselves. Although our findings with brain mitochondria suggest potential unwanted MJ effects, we did not observe overt neurotoxicity at therapeutic dosages in vivo (data not shown). This suggests that either MJ does not cross the blood-brain barrier or that at the levels we administered, it was not toxic to brain cells while exhibiting selective cytotoxicity for cancer cells. This selectivity is not only dependent on the high level of hexokinase bound to mitochondria in cancer cells, but probably also dependent on other cancer-specific characteristics, for example, other attributes peculiar to mitochondria in cancer cells.
In conclusion, MJ binds in a specific manner to mammalian hexokinase to disrupt its interaction with VDAC, leading to detachment of hexokinase from mitochondria and cytochrome c release. As such, MJ is the first anticancer agent to act in this manner. Moreover, we provide the first demonstration that in four cancer cell types (murine melanoma B16, murine colon carcinoma CT26, murine B cell leukemia BCL1, human T lymphoblastic leukemia cell line Molt-4), both hexokinase I and hexokinase II are expressed and bound to mitochondria, and that MJ detaches both bound hexokinase types from MF isolated from all of these cells to a similar extent. These findings allow us to hypothesize that MJ acts as a broad-spectrum hexokinasedetaching anticancer agent, taking advantage of the distinct energy metabolism of cancer cells.
Materials and methods

Materials
All the reagents used were purchased from Sigma (St Louis, MO, USA), unless otherwise stated. Taxol was purchased from Mead Johnson (Princeton, NJ, USA). Hydroxyapatite (BioGel HTP) was purchased from Bio-Rad (Hercules, CA, USA). Celite was purchased from BDH (Poole, Dorset, UK). PcDNA3 plasmid was purchased from Invitrogen (Carlsbad, CA, USA). pcDNA3 HKII was kindly donated by Dr JE Wilson, State University of Michigan.
Animals
Animals were obtained from the breeding colony of Tel-Aviv University, Israel. Wistar female rats and ICR male mice were used for brain and liver extractions. BALB/c and C57BL male mice (7-to 8-week-old) were used to grow BCL1 leukemia, B16 melanoma and CT26 colon carcinoma tumors. Animal care and experimentation were approved by the Tel-Aviv University Institutional Animal Use and Care Committee.
Cancer cell lines and tumors CT26 is a murine colon carcinoma, B16 is a murine melanoma, BCL1 is a murine B-cell leukemia, Molt-4 is a human Tlymphoblastic leukemia cell line. All cell lines were purchased from ATCC (Rockville, MD, USA). The cells were maintained at 37 1C with 5% CO 2 . CT26 and B16 cells were maintained in Dulbecco's modified Eagle's medium (Biological Industries, Beit-Haemek, Israel), supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM sodium pyruvate and a 1:100 dilution of nonessential amino acids. Molt-4 and BCL1 cells were maintained in RPMI-1640 medium (Biological Industries), supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
BCL1 cells were grown in BALB/c mice as described . Solid tumor preparations: 10 6 CT26 or B16 cells were injected subcutaneously in both flanks. Tumors exhibiting no necrotic signs were excised upon reaching a diameter of 10-12 mm.
Isolation of MF
Mitochondrial fraction was prepared by mechanical lysis and differential centrifugation, as previously described (AzoulayZohar et al., 2004) .
Cytotoxicity determination
Cell death was determined by trypan blue exclusion (Fingrut and Flescher, 2002) or a hemacolor assay (Keisari, 1992) , as described previously.
Determination of cellular ATP levels Cellular ATP levels were determined as described previously .
Hexokinase detachment from mitochondria Mitochondrial fraction was incubated with the reagent of interest and pelleted by centrifugation.
Hexokinase activity Mitochondrial fraction was incubated with the different agents. Mitochondria-bound hexokinase was precipitated and the activity of hexokinase in the supernatant fraction was assayed spectrophotometrically, as described (Wilson, 1968; Al jamal, 2005) . Neither MJ nor JA added directly to the assay mixture influences hexokinase activity.
Hexokinase immunoblotting Hexokinase was assayed by western blotting using specific anti-hexokinase I or antihexokinase II antibodies (Santa-Cruz Biotechnology, Santa Cruz, CA, USA). Immunoblot images were digitized and the optical densities of specific antigen-antibody complexes were quantified using the Gene Gnome Imaging System supported by the Gene Tools software package (both from Syngene, Frederick, MD, USA).
Determination of cytochrome c release from MF Freshly isolated MF was incubated with MJ and the supernatants were assayed for released cytochrome c by western blotting as described (Azoulay-Zohar et al., 2004) .
Mitochondria swelling assay
Swelling of mitochondria in freshly isolated MF was measured as described (Gincel et al., 2001 ). Absorption at 520 nm was monitored.
Hexokinase I purification Rat brain hexokinase I was purified according to Wilson (1989) and as described previously (Azoulay-Zohar et al., 2004) .
SPR analysis of jasmonate-hexokinase interactions
Surface plasmon resonance using the ProteOn XPR36 system (Bio-Rad Laboratories, Haifa, Israel) was employed to study the direct interaction of MJ with hexokinase I. Purified ligands were diluted in 10 mM Na acetate at pH 4 and 4.5, respectively and coupled to a general layer medium sensor surface activated with 37.5 mg/ml N-ethyl-N 0 -(3 0 -dimethylaminopropyl) carbodiimide hydrochloride and 7.5 mg/ml N-hydroxysuccinimide. Ligands were added to saturate the chip. The basic signal of hexokinase at saturation was between 8200 and 9000 relative units (RU), whereas that of IgG was 10500 RU. MJ and JA were injected onto the sensor chip. All experiments were performed at a flow rate of 50 ml/min, at 25 1C. The maximal relative units were about 60 RU (Hamilton et al., 2007) . Signals were normalized using appropriate negative controls.
VDAC purification, reconstitution, channel-activity recording and analysis Voltage-dependent anion channel was purified as described in Gincel et al. (2001) . VDAC was reconstituted into a planar lipid bilayer, recorded and analysed as described in AzoulayZohar et al. (2004) and Gincel et al. (2001) .
Cell transfections CT26 cells were transfected with pcDNA3-HKII or pcDNA3, using FuGene HD transfection reagent (Roche, Basel, Switzerland), according to the manufacturer's instruction followed by selection using G418.
Statistical analysis
Results are presented as mean ± s.e. of n independent experiments. Statistical significance was determined where appropriate, using analysis of variance. Po0.05 (asterisk) was considered statistically significant.
